Regeneron and Sanofi Announce Approval of DUPIXENT® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union

Thursday, September 28, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

First targeted biologic in the European Union to receive marketing authorization for use in atopic dermatitis

Contacts Regeneron:

Media Relations

Investor Relations

Arleen Goldenberg

Manisha Narasimhan, Ph.D.

Tel: + 1 (914) 847-3456   

Tel: +1 (914) 847-5126

Mobile: +1 (914) 260-8788

[email protected]         

[email protected]

Contacts Sanofi:

Media Relations

Investor Relations

Ashleigh Koss

George Grofik

Tel: 908-981-8745

Tel: +33 (0) 1 53 77 94 69

[email protected] 

[email protected]



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook